Skip to main content
Fig. 2 | Trials

Fig. 2

From: Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial

Fig. 2

Psoriasis Areas Severity Index (PASI) score, body surface area for psoriasis (BSA) score, Visual Analog Score (VAS), and Dermatology Life Quality Index (DLQI) score in the Chinese herbal medicine (CHM) and placebo groups. (a) PASI scores; (b) BSA scores; (c) VAS scores; and (d) DLQI scores. Comparison of changes of PASI (t = 1.764, P = 0.098), BSA (t = 0.523, P = 0.610), VAS (t = -0.079, P = 0.938), and DLQI (t = 0.845, P = 0.411) after treatment between the two groups. P < 0.05 indicated a significant difference between groups

Back to article page

Trials

ISSN: 1745-6215